Health Care Equipment

ReShape Lifesciences

ReShape Lifesciences Inc Restores Compliance With NASDAQ's Minimum Stockholders' Equity Requirements

ReShape Lifesciences Announces Layoffs and Updates Merger and Asset Sale Agreements

ReShape Lifesciences Raises $2.6 Million Through Stock Offering

ReShape Lifesciences and Recon Supply Sign Exclusive Distribution Agreement for Medical Products

ReShape Lifesciences Inc. public offering

ReShape Lifesciences Receives EU MDR Certification

ReShape Lifesciences Announces Merger with Vyome Therapeutics

ReShape Lifesciences Reports Q1 2025 Financials and Executes Reverse Stock Split

ReShape Lifesciences released FY2025 Q1 earnings on May 20 (EST), actual revenue USD 1.113M, actual EPS USD 18.9782

ReShape Lifesciences Inc Submits Up to $50 Million Shelf Offering Application

ReShape Presents Clinical Data for Diabetes Neuromodulation Device

ReShape Lifesciences Gastric Balloon System Patent Approved by US

ReShape Lifesciences® Receives Patent for Diabetes Treatment Technology

Reshape Signs Exclusive Distribution Agreement in the U.S. Neuromuscular Rehabilitation Market

ReShape Lifesciences released FY2024 earnings on April 4 (EST), actual revenue USD 8.006 M (forecast USD 9.994 M), actual EPS USD -345.7304 (forecast USD -652.4992)

ReShape Lifesciences released FY2024 Q4 earnings on April 4 (EST), actual revenue USD 1.805 M (forecast USD 3.173 M), actual EPS USD -61.7093 (forecast USD -101.4998)

ReShape Lifesciences FY2024 Q4 Earnings Release on April 10 During-Market EST, Forecasted Revenue 3.173 M USD, EPS -4.06 USD

ReShape Lifesciences Receives Notification of Allowance in the United States

ReShape Lifesciences Obtains US Patent for Vagus Nerve Modulation Technology to Treat Type 2 Diabetes

ReShape Lifesciences Announces $6 Million Public Offering to Support Weight Loss and Metabolic Health Solutions

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ATNF

ATNFW

RSLS

LABU

SBIO

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News

StockTitan

180 Life Sciences

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM)

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Global X HealthTech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News

Restart Life Sciences Corp. has appointed Lindsay Hamelin as an Independent Director, effective immediately. With over 20 years of experience in capital markets and corporate finance, she will provide oversight for the company's strategic growth. CEO Steve Loutskou expressed confidence in her ability to enhance shareholder value and support the company's expansion in the functional food and CPG markets. The appointment aims to strengthen the board as Restart Life continues its growth strategy and disciplined capital allocation.

Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors | NMLSF Stock News

Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY | NMLSF Stock News

Invesco Biotechnology & Genome ETF

Amazon

Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY | NMLSF Stock News

SAVU

Restart Life Sciences Corp. announced that its subsidiary, Holy Crap Foods, has sold over 500,000 units from January 2023 to March 2026, indicating strong consumer adoption. The company aims to expand its market presence in Canada, the U.S., and the Caribbean, focusing on gut health and wellness products. CEO Steve Loutskou emphasized the importance of this milestone for brand recognition and ongoing growth. Restart Life is committed to developing a diversified wellness platform, integrating gut and brain health products, and enhancing distribution and brand awareness.

Biolife4d Corp

SPDR S&P Health Equip

Direxion S&P Biotech Bear 3X

iShares US Medical Devices

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption | NMLSF Stock News

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

HIND

Cullen Investment Group LTD. has reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 60.7%, now holding 8,740 shares valued at $744,000. This change was reported in their recent SEC filing. Other institutional investors have also adjusted their positions in the company. Edwards Lifesciences shares opened at $82.71, with a market cap of $48.04 billion. The company reported earnings of $0.58 per share, missing estimates, but revenue increased by 13.3% year-over-year. Analysts have mixed ratings on the stock, with an average target price of $96.14.

Market Beat

Vyome

Edwards Lifesciences

Lifecore Biomedical

Cullen Investment Group LTD. Has $744,000 Holdings in Edwards Lifesciences Corporation $EW

ZYXIQ

GLSI

Sentynl Therapeutics has partnered with PRG S&T to license Progerinin, an investigational drug for treating Hutchinson-Gilford Progeria Syndrome (HGPS). The drug is currently in a Phase IIA trial, with results expected by mid-2026. Sentynl will gain full rights to Progerinin upon achieving specific milestones. This agreement enhances Sentynl's portfolio aimed at addressing rare diseases, reflecting their commitment to improving the lives of HGPS patients.

Pharmaceutical Technology

ZYNEX INC

Greenwich Lifesciences

Sentynl and PRG partner for Progerinin licence

ReShape Lifesciences(RSLS.US)

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio | NMLSF Stock News

Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors | NMLSF Stock News

Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY | NMLSF Stock News

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption | NMLSF Stock News

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

Cullen Investment Group LTD. Has $744,000 Holdings in Edwards Lifesciences Corporation $EW

Sentynl and PRG partner for Progerinin licence